论文部分内容阅读
我国是病毒性肝炎高发区,HBV感染率达57％,无症状HBV携带者(AsC)1．2亿人,平均年发病约140万人,慢性乙型肝炎(CHB)患者约为2800万人,肝硬化患者500万人,肝癌患者50万人。我国CHB病人的高风险是肝硬化,肝硬化病人由于发生肝细胞癌或出现非肿瘤性并发症如门静脉高压、肝衰竭而有较高的死亡率,严重地危害人们的身心健康。尽管用于治疗HBV感染的药物很多,但其疗效均不甚理想,如国际上公认的干扰素仅对20％-30％的病人有效;拉米夫定引起耐药变异,停药反跳等是非常棘手的难题,使人们必须寻找更好的治疗方案。近年,通过特异性免疫调节,诱生细胞免疫应答,已成为CHB治疗的研究热点。本文就国内外的研究成果进行综述。
China is a high incidence of viral hepatitis with HBV infection rate of 57%, 120 million asymptomatic HBV carriers (AsC), with an average annual incidence of about 1.4 million people, about 28 million people with chronic hepatitis B (CHB) 5 million people with cirrhosis and 500,000 people with liver cancer. The high risk of CHB patients in our country is cirrhosis of the liver. Patients with cirrhosis have higher mortality due to occurrence of hepatocellular carcinoma or non-neoplastic complications such as portal hypertension and liver failure, which seriously endanger people’s physical and mental health. Although a lot of drugs for the treatment of HBV infection, but its efficacy are less than ideal, such as internationally recognized interferon effective only in 20% -30% of patients; resistance to lamivudine-induced withdrawal and withdrawal and so on It is a very difficult problem, so people have to find a better treatment plan. In recent years, through specific immune regulation, induced cellular immune response, CHB has become the treatment of hot spots. This article reviews the research results at home and abroad.